Overview

The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

Status:
Terminated
Trial end date:
2014-05-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Afferent Pharmaceuticals, Inc.